NDC 51662-1420
NALBUPHINE HCI
Nalbuphine Hci
NALBUPHINE HCI is a Intramuscular; Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Hf Acquisition Co Llc, Dba Healthfirst. The primary component is Nalbuphine Hydrochloride.
| Product ID | 51662-1420_96139914-0709-7b58-e053-2995a90a7308 |
| NDC | 51662-1420 |
| Product Type | Human Prescription Drug |
| Proprietary Name | NALBUPHINE HCI |
| Generic Name | Nalbuphine Hci |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS |
| Marketing Start Date | 2019-10-29 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA070915 |
| Labeler Name | HF Acquisition Co LLC, DBA HealthFirst |
| Substance Name | NALBUPHINE HYDROCHLORIDE |
| Active Ingredient Strength | 10 mg/mL |
| Pharm Classes | Competitive Opioid Antagonists [MoA],Opioid Agonist/Antagonist [EPC],Partial Opioid Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |